Supply Chain | September 28, 2021
SpeeDx and SynGenis partner for custom oligonucleotide synthesis
The investment will increase SpeeDx internal capacity to scale up manufacturing
The investment will increase SpeeDx internal capacity to scale up manufacturing
One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
The lab will offer over 4,000 clinical tests and profiles and can conduct over 20,000 sample tests per month.
It is the first-ever approval in India for the treatment of Female Pattern Hair Loss (FPHL) and will be available only on prescription by a dermatologist
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
The company has been sold to Shinshin Pharmaceuticals
The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests
This facility will integrate with existing Max hospitals and create a 2,300-bed contiguous medical hub spread over 23 acres. The first phase is to be ready by 2024
Subscribe To Our Newsletter & Stay Updated
